- Home
- LIXT vs GLMD Comparison
LIXT vs GLMD Comparison
Compare LIXT & GLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LIXT
- GLMD
- Stock Information
- Founded
- LIXT 2005
- GLMD 2000
- Country
- LIXT United States
- GLMD Israel
- Employees
- LIXT N/A
- GLMD N/A
- Industry
- LIXT Biotechnology: Pharmaceutical Preparations
- GLMD Biotechnology: Pharmaceutical Preparations
- Sector
- LIXT Health Care
- GLMD Health Care
- Exchange
- LIXT Nasdaq
- GLMD Nasdaq
- Market Cap
- LIXT 3.0M
- GLMD 3.0M
- IPO Year
- LIXT N/A
- GLMD 2014
- Fundamental
- Price
- LIXT $0.74
- GLMD $1.81
- Analyst Decision
- LIXT
- GLMD Hold
- Analyst Count
- LIXT 0
- GLMD 1
- Target Price
- LIXT N/A
- GLMD N/A
- AVG Volume (30 Days)
- LIXT 82.2K
- GLMD 364.3K
- Earning Date
- LIXT 08-07-2025
- GLMD 05-22-2025
- Dividend Yield
- LIXT N/A
- GLMD N/A
- EPS Growth
- LIXT N/A
- GLMD N/A
- EPS
- LIXT N/A
- GLMD N/A
- Revenue
- LIXT N/A
- GLMD N/A
- Revenue This Year
- LIXT N/A
- GLMD N/A
- Revenue Next Year
- LIXT N/A
- GLMD N/A
- P/E Ratio
- LIXT N/A
- GLMD N/A
- Revenue Growth
- LIXT N/A
- GLMD N/A
- 52 Week Low
- LIXT $0.64
- GLMD $1.15
- 52 Week High
- LIXT $3.00
- GLMD $23.80
- Technical
- Relative Strength Index (RSI)
- LIXT 30.79
- GLMD 61.13
- Support Level
- LIXT $0.64
- GLMD $1.63
- Resistance Level
- LIXT $0.93
- GLMD $1.94
- Average True Range (ATR)
- LIXT 0.13
- GLMD 0.12
- MACD
- LIXT -0.05
- GLMD 0.01
- Stochastic Oscillator
- LIXT 16.99
- GLMD 69.77
About LIXT Lixte Biotechnology Holdings Inc.
Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.
About GLMD Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development of Aramchol. exclusively on developing Aramchol for the treatment of liver disease and were previously developing Aramchol for primary sclerosing cholangitis, PSC, and exploring the feasibility of developing Aramchol for other fibro-inflammatory indications outside of NASH and fibrosis. The company is currently seeking to advance the development of Aramchol for oncological indications outside of NASH and fibrosis.